BOARD OF DIRECTORS LIPUM
Ulf Björklund, Chairman of the Board
Mr. Björklund is M.Sc. in Pharmacy with more than 30 years of experience from the pharmaceutical industry, which ranges from pharmaceutical discovery and development of new drugs to diagnostics – from research to marketing. Prior engagements include CEO of Aprea (oncology) and CEO of OxyPharma (autoimmune diseases). Before that he held several positions within Pharmacia covering clinical research in many therapeutic areas of which the majority of the time in managerial positions. Mr. Björklund has experience in managing partner collaborations, financing and dealing with regulatory authorities in Europe and US. Mr. Björklund currently serves as board member in TikoMed AB and MedicaNatumin AB.
Professor Olle Hernell
Olle Hernell, MD, PhD, Professor of pediatrics and former head of Pediatrics at the Department of Clinical Sciences, Umeå University. He has more than 30 year experience as senior consultant, responsible for pediatric gastroenterology, hepatology and nutrition. He discovered the bile salt-stimulated lipase (BSSL) in human milk and is internationally well known for his BSSL research, clarifying its structure, characteristics and physiological function in fat digestion and its role in inflammation. Prof. Hernell´s research spans from basic science to clinical trials, including a recent phase III RCT conducted by Swedish Orphan Biovitrum (Sobi). He has published close to 300 peer reviewed scientific papers, trained more 20 PhD students, served on/or chaired many national and international committees and working groups. He is an inventor on several patents and has long experience of collaboration with industry.
Professor Lennart Lundberg
Prof. PhD. Lundberg has over 30 years in the pharmaceutical and biotech industry. His most recent position was within the management team of AnaMar AB as VP of Intellectual Property. Before that prof. Lundberg was at AstraZeneca AB (20 years), where his latest positions were as a Business Development Manager as well as being responsible for biotech patents at the cardiovascular and gastrointestinal business units. He has also worked within Target Discovery at AstraZeneca as principal scientist for many years. Prof. Lundberg joined Astra AB in 1989 to work as Project Leader for a recombinant protein drug development project. Prof. Lundberg has 75 papers published in the fields of biochemistry, biotechnology and gene technology connected to his expertise in protein engineering. He is also an inventor of several biotech patents.
Dr Kristian Sandberg
Dr Kristian Sandberg is an associate professor in immunology and an experienced leader in the pharmaceutical industry’s research and development. Sandberg has over 20 years’ experience from AstraZeneca in various functions within R&D, primarily with project leader responsibilities. He has experiences from the development of both protein and conventional small molecule based drugs from concept to clinical Phase II studies, in the field of neuroscience as well as respiratory, inflammatory and autoimmune diseases. Sandberg is active as an affiliated researcher to the Karolinska Institute and has had various assignments within the Foundation for Strategic Research. Since 2015, Sandberg holds the position as Director for the Drug Discovery Platform at Science for Life Laboratories (SciLifeLab) at Uppsala University. In addition to this responsibility, he was project leader for the development and optimization of a therapeutic antibody directed towards bile salt-stimulated lipase (BSSL). Sandberg sits on the board of Toleranzia AB, listed on the Spotlight Market. Sandberg is also a co-founder and board member of PharmaPrecision AB.